LONDON, March 14, 2014 /PRNewswire/ --

The trading session on Thursday, March 13, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,108.89, down 1.41% and the NASDAQ Composite closed at 4,260.42, down 1.46%. The S&P 500 finished the session 1.17% lower at 1,846.34. The losses were broad based as nine of ten sectors ended the session in negative. Investor-Edge.com looks at some of the equities which were most active during the session. These include Cell Therapeutics Inc. (NASDAQ:CTIC), Yandex N.V. (NASDAQ:YNDX), Himax Technologies Inc. (NASDAQ:HIMX), and CytRx Corp. (NASDAQ:CYTR). Free research on these four companies can be accessed at:

http://investor-edge.com/register

On Thursday, shares in Cell Therapeutics Inc. recorded heavy trading as a total of 13.27 million shares changed hands, against a three-month average volume of 5.68 million shares. The stock finished the day at $3.94, down 3.90%, and at an intraday range of $3.87 and $4.22. However, Cell Therapeutics Inc.'s shares have gained 4.51% in the past three trading sessions, 15.88% in the last one month, and 106.28% on YTD basis. The S&P 500 Health Care Sector Index mapped a gain of 1.14% in the last one month, while the NASDAQ Composite Index went up by 0.47% during the same period. The stock is trading above its 50-day and 200-day moving averages of $3.28 and $1.90, respectively. The company's shares are trading at an RSI of 65.41. Sign up and read the free notes on CTIC at:

http://www.Investor-Edge.com/03142014/CTIC/report.pdf

Yandex N.V.'s stock saw heavy trading as a total of 15.16 million shares changed hands on Thursday, as compared with the three-month average volume of 3.83 million shares. The stock closed the day at $29.16, down 8.42%, after trading between $28.65 and $31.60 during the session. Shares of the company traded at a PE ratio of 26.42. Yandex N.V.'s shares have lost 12.64% in the past three trading sessions, 27.62% in the last one month, and 32.42% on YTD basis. The S&P 500 Information Technology Sector Index mapped a gain of 5.71% in the last three months, while the NASDAQ Composite Index gained 6.48% during the same period. The stock is trading below its 50-day and 200-day moving averages of $38.93 and $35.48, respectively. The company's shares have an RSI of 32.09. The complimentary notes on YNDX can be downloaded as in PDF format at:

http://www.Investor-Edge.com/03142014/YNDX/report.pdf

Shares in Himax Technologies Inc. recorded heavy trading as a total of 14.82 million shares changed hands on Thursday, as compared with the three-month average volume of 8.14 million shares. The stock ended the day at $14.74, down 5.81%, after fluctuating between $14.59 and $16.15 during the session. The company's shares traded at a PE ratio of 40.16. Himax Technologies Inc.'s shares have declined 4.90% in the past three trading sessions, while gaining 4.32% in the last one month, and 0.20% on YTD basis. The S&P 500 Information Technology Sector Index declined 0.54% in the last one month, while the NASDAQ Composite Index was up by 0.47% during the same period. Shares of the company are trading above its 50-day and 200-day moving averages of $14.06 and $9.77, respectively. The stock is trading at an RSI of 64.73. Register for free on Investor-Edge and access the latest research on HIMX at:

http://www.Investor-Edge.com/03142014/HIMX/report.pdf

CytRx Corp.'s shares saw heavy trading as a total of 11.07 million shares were exchanged, against a three-month average volume of 3.97 million shares. On Thursday, the stock closed the day at $4.17, down 12.76%, after vacillating between $4.10 and $4.86. CytRx Corp.'s shares have fallen by 18.24% in the past three trading sessions, 33.60% in the last one month, and 33.49% on YTD basis. The S&P 500 Health Care Sector Index mapped a gain of 9.22% in the last three months, while the NASDAQ Composite Index was up by 6.48% during the same period. The stock is trading below its 50-day moving average. CytRx Corp.'s 200-day moving average of $3.58 is below the 50-day moving average of $6.47. The company's shares have an RSI of 32.11. The complete research on CYTR is available for free at:

http://www.Investor-Edge.com/03142014/CYTR/report.pdf

About Investor-Edge.com

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

=============

EDITOR NOTES:

============= 


        
        - This is not company news. We are an independent source and our views do
          not reflect the companies mentioned.
        - Information in this release is fact checked and produced on a best efforts
          basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human
          and are prone to make mistakes. If you notice any errors or omissions, please notify
          us below.
        - This information is submitted as a net-positive to companies mentioned, to
          increase awareness for mentioned companies to our subscriber base and the investing
          public.
        - If you wish to have your company covered in more detail by our team, or wish
          to learn more about our services, please contact us at pubco [at] Investor-edge.com.
        - For any urgent concerns or inquiries, please contact us at compliance [at]
          Investor-edge.com.
        - Are you a public company? Would you like to see similar coverage on your
          company? Send us a full investors' package to research [at] Investor-edge.com for
          consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-edge. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Investor-edge in this article or report according to the Procedures outlined by Investor-edge. Investor-edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge